地榆活性成分抑制肿瘤血管生成作用及机理研究

被引:0
作者
于娅
机构
[1] 成都中医药大学
关键词
地榆; 鞣花酸; 肿瘤血管生成; S180; H22; HUVEC; PDGFB; p-STAT3; STAT3;
D O I
暂无
年度学位
2015
学位类型
硕士
导师
摘要
目的:筛选地榆抗肿瘤血管生成活性成分,研究地榆活性成分抗肿瘤血管生成作用,并探讨其作用机制。方法:①地榆抗肿瘤血管生成活性部位筛选:采用系统溶剂提取法制备地榆石油醚、氯仿、乙酸乙酯、正丁醇、水共5个不同极性部位;以HUVEC、MCF-7、 Bel-7402三种细胞增殖模型,采用SRB染色法筛选地榆抗肿瘤血管生成的活性部位:②活性部位馏分分离、活性馏分筛选与鉴定:采用制备型HPLC从地榆正丁醇活性部位中分离不同馏分;以HUVEC、MCF-7、Bel-7402三种细胞增殖模型,采用SRB染色法筛选地榆抗肿瘤血管生成活性馏分;面积归一化法计算样品的纯度,MS和H-NMR对活性成分进行结构鉴定。③活性成分(鞣花酸)抗肿瘤血管作用研究:以HUVEC细胞模型,采用SRB法、划痕法及Matrigel体外成管实验分别考察鞣花酸对HUVEC增殖、迁移及小管形成的影响;体内建立S180、H22皮下荷瘤小鼠模型,随机分为模型组(0.5%CMC溶液)、环磷酰胺组(阳性对照,20 mg/kg)、鞣花酸高、中、低(200、100、50 mg/kg)剂量组,连续给药10 d,观察鞣花酸对荷瘤小鼠肿瘤生长、体重、胸腺指数及脾脏指数的影响,免疫组化法检测肿瘤微血管密度。④鞣花酸抗肿瘤血管作用机理研究:采用RT-PCR法、ELISA法、Western blotting法分别观察鞣花酸对HUVEC细胞PDGFB mRNA表达、对细胞上清中PDGFB分泌及对细胞中PDGFB、 STAT3、p-STAT3蛋白表达水平的影响;免疫组化法测定S180、H22荷瘤小鼠肿瘤组织中PDGFB、p-STAT3及STAT3的表达情况。结果:①地榆正丁醇提取部位显著抑制HUVEC、MCF-7、Bel-7402三种细胞增殖(P<0.01或P<0.05)。②从正丁醇部位中共获得22种馏分(1-22#);5#馏分(20μg/mL)对HUVEC、MCF-7、Bel-7402三种细胞增殖均有显著抑制作用(P<0.01或P<0.05);MS、H-NMR结果显示,5#馏分为鞣花酸。③鞣花酸(20、10、5μg/mL)显著抑制HUVEC增殖、迁移和小管形成(P<0.01或P<0.05),其增殖抑制作用呈时间和浓度依赖性,其迁移和小管形成抑制作用呈剂量依赖性。④鞣花酸(200,100,50 mg/kg)显著抑制S180、H22小鼠肿瘤生长,对小鼠体重无影响。鞣花酸高剂量组对S 180、H22小鼠脾脏指数较模型组显著上升(P<0.05)。鞣花酸高、中剂量组能显著降低S180、H22小鼠肿瘤微血管密度(P<0.05)。⑤鞣花酸(20、10、5μg/mL)能显著降低HUVEC细胞中PDGFB基因和蛋白表达水平(P<0.01或P<0.05),降低STAT3蛋白的磷酸化水平(P<0.01或P<0.05),而对STAT3蛋白表达总量无变化。与模型组比较,鞣花酸给药组在S180、H22两种瘤体中PDGFB.p-STAT3和STAT3的表达明显降低。结论:地榆活性成分鞣花酸具有良好的抗肿瘤及抗肿瘤血管生成作用,其机制可能与下调PDGFB表达并抑制下游STAT3的蛋白表达及磷酸化有关。
引用
收藏
页数:72
共 50 条
[1]
Ellagic acid induces a dose- and time-dependent depolarization of mitochondria and activation of caspase-9 and-3 in human neuroblastoma cells [J].
Alfredsson, Christina Fjaeraa ;
Ding, Menglei ;
Liang, Qiu-Li ;
Sundstrom, Birgitta E. ;
Nanberg, Eewa .
BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (01) :129-135
[2]
Compound K, an intestinal metabolite of ginsenosides, inhibits PDGF-BB-induced VSMC proliferation and migration through G1 arrest and attenuates neointimal hyperplasia after arterial injury [J].
Park, Eun-Seok ;
Lee, Kang Pa ;
Jung, Seung Hyo ;
Lee, Dong-Youb ;
Won, Kyung Jong ;
Yun, Yeo-Pyo ;
Kim, Bokyung .
ATHEROSCLEROSIS, 2013, 228 (01) :53-60
[3]
Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice [J].
Zhao, Min ;
Tang, Su-Ni ;
Marsh, Justin L. ;
Shankar, Sharmila ;
Srivastava, Rakesh K. .
CANCER LETTERS, 2013, 337 (02) :210-217
[4]
Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer [J].
Wang, Neng ;
Wang, Zhi-Yu ;
Mo, Sui-Lin ;
Loo, Tjing Yung ;
Wang, Dong-Mei ;
Luo, Hai-Bin ;
Yang, De-Po ;
Chen, Yu-Ling ;
Shen, Jian-Gang ;
Chen, Jian-Ping .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) :943-955
[5]
Targeting tumor cell motility to prevent metastasis [J].
Palmer, Trenis D. ;
Ashby, William J. ;
Lewis, John D. ;
Zijlstra, Andries .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (08) :568-581
[6]
A phase II; single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.[J].Katherine M. Bell-McGuinn;Carolyn M. Matthews;Steffan N. Ho;Minal Barve;Lucy Gilbert;Richard T. Penson;Ernst Lengyel;Rameshraja Palaparthy;Kye Gilder;Artemios Vassos;William McAuliffe;Sara Weymer;Jeremy Barton;Russell J. Schilder.Gynecologic Oncology.2010, 2
[7]
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy [J].
Murray, Alexandra ;
Little, Samantha J. ;
Stanley, Paul ;
Maraveyas, Anthony ;
Cawkwell, Lynn .
ONCOLOGY REPORTS, 2010, 24 (04) :1049-1058
[8]
A randomized phase 2 study of etaracizumab; a monoclonal antibody against integrin α.[J].PeterHersey;JeffreySosman;StevenO'Day;JonRichards;AgopBedikian;ReneGonzalez;WilliamSharfman;RobertWeber;TheodoreLogan;ManuelaBuzoianu;LuzHammershaimb;John M.Kirkwood.Cancer.2010, 6
[9]
The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial [J].
Kim, Sungwoo ;
Gaber, Mostafa W. ;
Zawaski, Janice A. ;
Zhang, Feng ;
Richardson, Mekel ;
Zhang, Xin A. ;
Yang, Yunzhi .
BIOMATERIALS, 2009, 30 (27) :4743-4751
[10]
Investigation of extrinsic and intrinsic apoptosis pathways of new clerodane diterpenoids in human prostate cancer PC-3 cells.[J].Dong-Ming Huang;Ya-Ching Shen;Chi Wu;Yao-Ting Huang;Fan-Lu Kung;Che-Ming Teng;Jih-Hwa Guh.European Journal of Pharmacology.2004, 1